SCHEMBL26124152

SCHEMBL26124152

c1ccc2c(c1)ccc1cc(-c3ccc(-c4cnc(-c5ccc(-c6cc7ccccc7c7ccccc67)cc5)nc4)cc3)ccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.45
▸ RAB9A P51151 5/20 0.45
▸ SMN1; SMN2 Q16637 4/20 0.45
▸ MAPT P10636 4/20 0.45
▸ LMNA P02545 2/20 0.45
▸ CYP11B1 P15538 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ NFKB1 P19838 2/20 0.44
▸ NFKB2 Q00653 2/20 0.44
▸ RELA Q04206 2/20 0.44
▸ HPRT1 P00492 3/20 0.41
▸ ALDH1A1 P00352 4/20 0.39
▸ HSD17B10 Q99714 3/20 0.39
▸ HIF1A Q16665 1/20 0.39
▸ CYP1B1 Q16678 1/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ KMT2A Q03164 2/20 0.39
▸ HPGD P15428 2/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831682 1.00 NPC1 (0.45) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL24910261 0.92 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL29832043 0.92 NPC1 (0.52) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL29831538 0.90 CYP11B1 (0.44) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL26125533 0.90 CYP11B1 (0.44) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL29831799 0.84 CYP11B1 (0.40) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL24909994 0.84 CYP11B1 (0.40) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL29832722 0.83 PDGFRB (0.48) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL26122111 0.83 PDGFRB (0.48) NPC1RAB9ASMN1; SMN2MAPTLMNA
SCHEMBL24686227 0.81 CYP11B1 (0.46) SMN1; SMN2MAPTCYP11B1HPRT1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240049595-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS HODOGAYA CHEMICAL CO., LTD. (JP) 2024-02-08 — — US disclosed
EP-4257585-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Hodogaya Chemical Co., Ltd. (JP) 2023-10-11 — — EP disclosed
EP-4257585-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE Hodogaya Chemical Co., Ltd. (JP) 2023-10-11 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240049595-A1 HETEROCYCLIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE, AND ELECTRONIC APPARATUS LAGE3, EED, EZH1 NPC1 2299/4885RAB9A 1592/4885SMN1; SMN2 3855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback